Valuation: Orion Oyj

Market Cap 11.39B 12.81B 10.64B 9.7B 18.21B 1,233B 18.47B 129B 49.78B 629B 48.06B 47.02B 2,024B P/E 2026 *
20.1x
P/E 2027 * 17x
Enterprise Value 11.3B 12.7B 10.55B 9.63B 18.06B 1,224B 18.32B 128B 49.39B 624B 47.68B 46.65B 2,008B EV / Sales 2026 *
5.39x
EV / Sales 2027 * 4.66x
Free-Float
90.5%
Yield 2026 *
2.4%
Yield 2027 * 2.68%
1 day+11.24%
1 month+11.24%
3 months+11.24%
6 months+16.59%
Current year+13.22%
1 month 92.05
Extreme 92.05
92.05
Current year 78.95
Extreme 78.95
92.05
1 year 78.95
Extreme 78.95
92.05
3 years 47.16
Extreme 47.16
92.05
5 years 37
Extreme 37
92.05
10 years 27.35
Extreme 27.35
92.05
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+11.24%-.--% - - 13.28B
-0.62%-0.10%+50.70%+114.07% 1,031B
-2.30%-3.90%+39.50%+66.07% 638B
-0.63%-1.94%+12.26%+74.38% 462B
-1.03%-2.88%+71.35%+39.69% 359B
-0.03%-3.91%+34.28%+39.35% 335B
-1.58%+0.39%+17.92%+25.77% 273B
-2.02%-3.20%+7.60%+8.38% 253B
-3.38%+0.29%+44.32%+51.54% 228B
-1.04%-2.56%+32.88%+96.82% 185B
Average +0.37%-0.36%+34.53%+57.34% 418.21B
Weighted average by Cap. -0.49%-0.35%+38.05%+69.18%

Financials

2026 *2027 *
Net sales 2.1B 2.36B 1.96B 1.79B 3.35B 227B 3.4B 23.68B 9.16B 116B 8.85B 8.66B 373B 2.37B 2.67B 2.22B 2.02B 3.79B 257B 3.85B 26.8B 10.37B 131B 10.01B 9.8B 422B
Net income 566M 636M 528M 482M 904M 61.25B 917M 6.39B 2.47B 31.21B 2.39B 2.34B 101B 668M 751M 624M 569M 1.07B 72.34B 1.08B 7.54B 2.92B 36.87B 2.82B 2.76B 119B
Net Debt -89.76M -101M -83.83M -76.48M -143M -9.72B -146M -1.01B -392M -4.95B -379M -371M -15.95B -333M -374M -311M -284M -532M -36.06B -540M -3.76B -1.46B -18.38B -1.4B -1.37B -59.17B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
80.90EUR
Average target price
76.67EUR
Spread / Average Target
-5.23%

Quarterly revenue - Rate of surprise